Literature DB >> 33624840

Anti-arrhythmic investigations in large animal models of atrial fibrillation.

Arnela Saljic1, Thomas Jespersen1, Rikke Buhl2.   

Abstract

Atrial fibrillation (AF) constitutes an increasing health problem in the aging population. Animal models reflecting human phenotypes are needed to understand the mechanisms of AF, as well as to test new pharmacological interventions. In recent years, a number of large animal models, primarily pigs, goats, dog and horses have been used in AF research. These animals can to a certain extent recapitulate the human pathophysiological characteristics and serve as valuable tools in investigating new pharmacological interventions for treating AF. This review focuses on anti-arrhythmic investigations in large animals. Initially, spontaneous AF in small and large mammals is discussed. This is followed by a short presentation of frequently used methods for inducing short- and long-term AF. The major focus of the review is on anti-arrhythmic compounds either frequently used in the human clinic (ranolazine, flecainide, vernakalant and amiodarone) or being promising new AF medicine candidates (IK,Ach , ISK,Ca and IK2P blockers). LINKED ARTICLES: This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc.
© 2021 The British Pharmacological Society.

Entities:  

Keywords:  Antiarrhythmic drugs; atrial fibrillation; ion channels; pharmacology

Mesh:

Substances:

Year:  2021        PMID: 33624840     DOI: 10.1111/bph.15417

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

Review 1.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

2.  The impact of an atrial septal defect on the progression of atrial tachypacing-induced atrial fibrillation in a Danish Landrace pig: A case report.

Authors:  Arnela Saljic; Julie Norup Hertel; Caroline Leonhardt; Sarah Dalgas Nissen; Dobromir Dobrev; Thomas A Jepps; Thomas Jespersen; Stefan Michael Sattler
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-17

Review 3.  Emerging Antiarrhythmic Drugs for Atrial Fibrillation.

Authors:  Arnela Saljic; Jordi Heijman; Dobromir Dobrev
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

Review 4.  Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation.

Authors:  Jesús Borrego; Adam Feher; Norbert Jost; Gyorgy Panyi; Zoltan Varga; Ferenc Papp
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-14

Review 5.  Paroxysmal Atrial Fibrillation in Horses: Pathophysiology, Diagnostics and Clinical Aspects.

Authors:  Sofie Troest Kjeldsen; Sarah Dalgas Nissen; Rikke Buhl; Charlotte Hopster-Iversen
Journal:  Animals (Basel)       Date:  2022-03-10       Impact factor: 2.752

6.  Increased fibroblast accumulation in the equine heart following persistent atrial fibrillation.

Authors:  Arnela Saljic; Merle Friederike Fenner; Joris Winters; Mette Flethøj; Caroline Eggert Eggertsen; Helena Carstensen; Sarah Dalgas Nissen; Eva Melis Hesselkilde; Arne van Hunnik; Ulrich Schotten; Ulrik Sørensen; Thomas Jespersen; Sander Verheule; Rikke Buhl
Journal:  Int J Cardiol Heart Vasc       Date:  2021-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.